CJC-1295 (without DAC) vs Tesamorelin

CJC-1295 (without DAC)

CJC-1295 without DAC (also known as Modified GRF 1-29 or Mod GRF) is a synthetic 29-amino acid peptide analogue of growth hormone-releasing hormone (GHRH) with four amino acid substitutions (positions 2, 8, 15, and 27) that confer resistance to DPP-IV enzymatic degradation. Its mechanism of action involves binding to GHRH receptors (GHRH-R) on anterior pituitary somatotroph cells, stimulating cAMP-mediated signaling that triggers growth hormone synthesis and secretion. The amino acid modifications extend the peptide's biological half-life from under 10 minutes (native GHRH) to approximately 30 minutes, enabling meaningful GH pulse amplification while still preserving physiological pulsatile release patterns. Research on this modified GHRH analogue demonstrates it produces GH elevations within 15-30 minutes of administration, with return to baseline within 2-3 hours, mimicking natural GH pulse kinetics. Studies suggest CJC-1295 without DAC may support skin thickness and collagen production through GH-mediated IGF-1 elevation (Ionescu and Bhatt, Growth Hormone and IGF Research). Compared to the DAC-conjugated version (CJC-1295 with DAC), the non-DAC form produces shorter, more discrete GH pulses rather than sustained 7-10 day GH elevation, which some research protocols prefer for mimicking physiological patterns. It is frequently paired with ghrelin mimetics like ipamorelin for synergistic effect. Store lyophilized powder at -20C; reconstitute with bacteriostatic water and refrigerate at 2-8C for up to 21 days. This peptide is studied by endocrinology research departments, anti-aging medicine laboratories, and body composition research centers investigating GHRH axis modulation.

Tesamorelin

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of the 44-amino acid human GHRH sequence with a trans-3-hexenoic acid modification at the N-terminus. It acts by binding to GHRH receptors on anterior pituitary somatotroph cells, stimulating pulsatile growth hormone (GH) release while preserving the natural hypothalamic-pituitary feedback axis. Tesamorelin received FDA approval (marketed as Egrifta) for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, based on pivotal trials demonstrating approximately 15-18% reduction in visceral adipose tissue over 26 weeks (Falutz et al., JAMA 2007). Beyond lipodystrophy research, studies published in Annals of Neurology (Baker et al., 2012) suggest tesamorelin may improve cognitive function in older adults with mild cognitive impairment by modulating IGF-1 levels in the central nervous system. Compared to direct GH administration, tesamorelin preserves physiological GH pulsatility rather than creating supraphysiological sustained GH levels, which research indicates may reduce the risk of insulin resistance associated with exogenous GH. Additional preclinical work has explored its role in peripheral nerve regeneration models. The lyophilized powder should be stored at controlled room temperature (20-25C) or refrigerated; reconstitute with sterile water and use within 24 hours or refrigerate for up to 14 days. This peptide is studied by endocrinology research labs, HIV metabolism centers, and neuroscience institutions investigating GH-IGF-1 axis modulation.

Frequently Asked Questions